LeMaitre Vascular Management
Management criteria checks 4/4
LeMaitre Vascular's CEO is George LeMaitre, appointed in Jun 1992, has a tenure of 34.17 years. total yearly compensation is $3.78M, comprised of 21.3% salary and 78.7% bonuses, including company stock and options. directly owns 6.4% of the company’s shares, worth $120.50M. The average tenure of the management team and the board of directors is 10.1 years and 23.6 years respectively.
Key information
George LeMaitre
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 21.33% |
| CEO tenure | 34.2yrs |
| CEO ownership | 6.4% |
| Management average tenure | 10.1yrs |
| Board average tenure | 23.6yrs |
Recent management updates
Recent updates
Seeking Alpha • Aug 13
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut
Summary LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT’s largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects. Valuation reset to 29x forward earnings appears overdone given 11% organic growth guidance, the balance sheet, and expanding biologics mix. Read the full article on Seeking Alpha
Narrative Update • Aug 11
LMAT: Future Cash Returns May Support Post Selloff Entry And Premium P/E
LeMaitre Vascular's analyst price target has been revised from $118.75 to $110.00 as analysts factor in a slightly higher discount rate, more moderate revenue growth and profit margin expectations, and a lower assumed future P/E multiple, while also highlighting recent price volatility as an opportunity to reassess the stock's risk and reward profile. Analyst Commentary Recent Street research on LeMaitre Vascular reflects a mix of optimism about long term potential and caution around nearer term execution and valuation.Analysis Article • Aug 07
LeMaitre Vascular, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
One of the biggest stories of last week was how LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) shares plunged 21% in the week...
New Narrative • Aug 07
Global Expansion Risks And Supply Constraints Will Shape A Cautious Yet Constructive Outlook
Catalysts About LeMaitre Vascular LeMaitre Vascular develops, manufactures and sells devices and tissues for vascular and cardiac surgery worldwide. What are the underlying business or industry changes driving this perspective?Analysis Article • Jun 20
LeMaitre Vascular (LMAT) Stock Could Be 20.9% Undervalued on Its International Growth Narrative
LeMaitre Vascular (LMAT) is back in focus after recent share price moves, with the stock last closing at US$93.95. Investors are weighing this level against the company’s fundamentals and recent return profile. See our latest analysis for LeMaitre Vascular. Recent momentum in LeMaitre Vascular has been mixed, with a 1-day share price return of 1.89% and a year to date share price return of 17.19%, while the 1-year total shareholder return stands at 15.94% and the 5-year total shareholder...Narrative Update • Jun 11
LMAT: Future Cash Returns May Support Raised 2026 Guidance And Premium P/E
Analysts have lifted their price target on LeMaitre Vascular by $25, citing updated assumptions around the discount rate, long term revenue growth, profit margins, and future P/E as key drivers of their revised view. Analyst Commentary Recent research updates on LeMaitre Vascular show a cluster of price target increases and a neutral initiation, providing a mix of both optimistic and cautious viewpoints on the stock.Narrative Update • May 28
LMAT: Future Cash Returns May Support Raised Earnings Guidance And Premium P/E
LeMaitre Vascular's analyst price target has been updated to $118.75 from $111.22, as analysts factor in revised fair value assumptions, a slightly lower discount rate, modestly adjusted revenue growth expectations, and a higher projected P/E multiple supported by recent research updates from multiple firms. Analyst Commentary Recent research updates show a cluster of higher price targets for LeMaitre Vascular, alongside at least one more neutral stance, giving you a mix of optimistic and cautious views to weigh.Narrative Update • Apr 27
LMAT: Future Cash Returns And Operating Leverage May Sustain Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular moves to $117 from $108. This reflects analysts' focus on recent double digit organic growth, margin expansion, strong cash flow, and better than expected Q4 results with operating leverage.Narrative Update • Apr 13
LMAT: Future Margin Discipline And Cash Returns May Support Current Premium
Narrative Update on LeMaitre Vascular The updated analyst price target for LeMaitre Vascular now reflects a modestly higher fair value estimate of about $111.22. This is supported by Street research that highlights continued double digit organic sales growth, material margin expansion, strong cash flow and operating leverage in the wake of better than expected Q4 results and guidance.Narrative Update • Mar 29
LMAT: Future Cash Returns And Margin Discipline May Sustain Current Premium
Narrative Update Analysts have raised LeMaitre Vascular's price targets by $10 to $12, now in a $105 to $117 range. They cite double digit organic revenue growth, margin expansion, strong cash flow, better than expected Q4 results, and operating leverage.Narrative Update • Mar 14
LMAT: Future Margin Execution And Capital Returns May Support Current Premium
Narrative Update on LeMaitre Vascular Our analyst fair value estimate for LeMaitre Vascular has been lifted from $109.22 to $111.00, reflecting updated price targets from $95 to $105 and from $108 to $117 as analysts point to double digit organic growth, margin expansion, and operating leverage following better than expected Q4 results and guidance. Analyst Commentary Recent price target increases to $105 and $117 signal that bullish analysts are incorporating stronger fundamentals into their models following the latest Q4 print and guidance.Narrative Update • Feb 28
LMAT: Future Margin Gains And Capital Returns May Sustain Current Premium
Analysts have increased their implied fair value estimate for LeMaitre Vascular by about $4 to roughly $109, citing recent price target increases to $105 and $117 that they attribute to double-digit organic sales growth, margin expansion and operating leverage. Analyst Commentary Bullish Takeaways Bullish analysts point to double digit organic sales growth as a key support for their higher fair value views, seeing current revenue trends as consistent with a premium valuation versus slower growing peers.Analysis Article • Feb 06
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysis Article • Jan 03
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Shares May Have Run Too Fast Too Soon
With a price-to-earnings (or "P/E") ratio of 34.1x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Analysis Article • Oct 26
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...Analysis Article • Aug 30
Here's Why LeMaitre Vascular (NASDAQ:LMAT) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analysis Article • Aug 06
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Could Be 25% Above Their Intrinsic Value Estimate
Key Insights LeMaitre Vascular's estimated fair value is US$68.59 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Jul 18
Is LeMaitre Vascular (NASDAQ:LMAT) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jun 18
Earnings Not Telling The Story For LeMaitre Vascular, Inc. (NASDAQ:LMAT)
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) price-to-earnings (or "P/E") ratio of 40.5x might make it look like a strong...Analysis Article • Apr 24
Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analysis Article • Apr 12
Does LeMaitre Vascular (NASDAQ:LMAT) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Mar 31
LeMaitre Vascular (NASDAQ:LMAT) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...Analysis Article • Mar 11
LeMaitre Vascular's (NASDAQ:LMAT) Shareholders Will Receive A Bigger Dividend Than Last Year
LeMaitre Vascular, Inc.'s ( NASDAQ:LMAT ) dividend will be increasing from last year's payment of the same period to...Analysis Article • Mar 02
Earnings Update: Here's Why Analysts Just Lifted Their LeMaitre Vascular, Inc. (NASDAQ:LMAT) Price Target To US$105
Shareholders might have noticed that LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) filed its yearly result this time last...Analysis Article • Feb 04
When Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it received a lot of...Analysis Article • Jan 22
We Ran A Stock Scan For Earnings Growth And LeMaitre Vascular (NASDAQ:LMAT) Passed With Ease
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Jan 15
LeMaitre Vascular: Losing Steam
Summary LeMaitre Vascular, Inc. has seen a 65% stock rise over 12 months but trades at high valuations with decelerating growth projections. Q3 results showed strong performance with 46% profit growth and 15.7% revenue increase, driven by grafts, patches, and carotid shunts. The stock has dipped some 15% recently. Buy the dip? An analysis around LeMaitre Vascular follows in the paragraphs below. Read the full article on Seeking AlphaAnalysis Article • Jan 09
A Look At The Fair Value Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Key Insights LeMaitre Vascular's estimated fair value is US$96.24 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Dec 22
LeMaitre Vascular (NASDAQ:LMAT) Has More To Do To Multiply In Value Going Forward
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Nov 24
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) 26% Price Boost Is Out Of Tune With Earnings
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) shares have had a really impressive month, gaining 26% after a shaky period...Seeking Alpha • Nov 03
LeMaitre Vascular: The Market Is Catching On To This Dividend Growth Story
Summary LeMaitre continues to expand in the peripheral vascular disease market, with recent revenue gains driven by premium pricing and international growth. Its strong dividend growth of 14.3% this year and double-digit CAGR over the past five years are particularly appealing. With a high-margin, low-competition niche and accelerating geographic expansion, LeMaitre remains well-positioned for sustained growth. Read the full article on Seeking AlphaAnalysis Article • Nov 02
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
As you might know, LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) just kicked off its latest quarterly results with some very...Analysis Article • Oct 08
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Potentially Undervalued?
While LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) might not have the largest market cap around , it saw a double-digit...Analysis Article • Sep 17
Investors Met With Slowing Returns on Capital At LeMaitre Vascular (NASDAQ:LMAT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
New Narrative • Sep 11
Expanding Market Reach And Calculated Acquisitions Set To Fuel Robust Revenue And Earnings Growth
Expansion in North America and new regulatory approvals in Europe and Asia-Pacific indicate potential revenue growth from increased market share and customer reach.Analysis Article • Sep 04
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Price In Tune With Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 17x, you may...Analysis Article • Aug 22
If EPS Growth Is Important To You, LeMaitre Vascular (NASDAQ:LMAT) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Jul 23
LeMaitre Vascular: A Small Cap With Best-In-Industry Growth
Summary I outline why LeMaitre Vascular is my top choice in the Health Care Equipment industry and one of the best small caps in the sector. LeMaitre has shown incredible revenue and EPS growth since its IPO and also offers a well-supported, fast-growing dividend. Despite a seemingly high valuation, further growth is expected. Read the full article on Seeking AlphaAnalysis Article • Jul 12
Is LeMaitre Vascular, Inc. (NASDAQ:LMAT) Worth US$85.0 Based On Its Intrinsic Value?
Key Insights LeMaitre Vascular's estimated fair value is US$70.02 based on 2 Stage Free Cash Flow to Equity Current...Analysis Article • Jun 18
Is There Now An Opportunity In LeMaitre Vascular, Inc. (NASDAQ:LMAT)?
LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), might not be a large cap stock, but it led the NASDAQGM gainers with a...Analysis Article • Jun 05
Return Trends At LeMaitre Vascular (NASDAQ:LMAT) Aren't Appealing
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...Analysis Article • May 02
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 49.8x LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) may be sending very bearish...Analysis Article • Apr 04
Is Now The Time To Put LeMaitre Vascular (NASDAQ:LMAT) On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$66m |
| Mar 31 2026 | n/a | n/a | US$62m |
| Dec 31 2025 | US$4m | US$806k | US$58m |
| Sep 30 2025 | n/a | n/a | US$53m |
| Jun 30 2025 | n/a | n/a | US$47m |
| Mar 31 2025 | n/a | n/a | US$45m |
| Dec 31 2024 | US$3m | US$622k | US$44m |
| Sep 30 2024 | n/a | n/a | US$41m |
| Jun 30 2024 | n/a | n/a | US$38m |
| Mar 31 2024 | n/a | n/a | US$34m |
| Dec 31 2023 | US$2m | US$593k | US$30m |
| Sep 30 2023 | n/a | n/a | US$27m |
| Jun 30 2023 | n/a | n/a | US$25m |
| Mar 31 2023 | n/a | n/a | US$21m |
| Dec 31 2022 | US$2m | US$568k | US$21m |
| Sep 30 2022 | n/a | n/a | US$21m |
| Jun 30 2022 | n/a | n/a | US$22m |
| Mar 31 2022 | n/a | n/a | US$27m |
| Dec 31 2021 | US$2m | US$473k | US$27m |
| Sep 30 2021 | n/a | n/a | US$28m |
| Jun 30 2021 | n/a | n/a | US$29m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$1m | US$311k | US$21m |
| Sep 30 2020 | n/a | n/a | US$19m |
| Jun 30 2020 | n/a | n/a | US$16m |
| Mar 31 2020 | n/a | n/a | US$18m |
| Dec 31 2019 | US$1m | US$438k | US$18m |
Compensation vs Market: George's total compensation ($USD3.78M) is about average for companies of similar size in the US market ($USD5.15M).
Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.
CEO
George LeMaitre (61 yo)
34.2yrs
Tenure
US$3,780,990
Compensation
Mr. George W. LeMaitre has been Chief Executive Officer of Lemaitre Vascular, Inc. since June 1992 and has been its Chairman since 2004. Mr. LeMaitre served as the President of Lemaitre Vascular from June...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 34.2yrs | US$3.78m | 6.4% $ 120.5m | |
| President & Director | 19.1yrs | US$1.27m | 0.029% $ 550.4k | |
| Chief Financial Officer | 1.4yrs | US$1.18m | 0.00088% $ 16.6k | |
| Senior Vice President of Operations | 21.6yrs | US$959.32k | 0.016% $ 308.6k | |
| Founder and Chairman of Scientific Advisory Board | 43.6yrs | US$138.40k | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Vice President of Marketing | 23.6yrs | no data | no data | |
| Senior Director of Human Resources | 6.6yrs | no data | no data | |
| Senior Vice President of Information Technology | 2.3yrs | no data | no data | |
| Senior Vice President of Sales – Central Europe | 2.3yrs | no data | no data | |
| Senior Vice President of Advanced Manufacturing Engineering | 3.6yrs | no data | no data | |
| Senior Vice President of Clinical | 13.6yrs | no data | no data |
10.1yrs
Average Tenure
52.5yo
Average Age
Experienced Management: LMAT's management team is seasoned and experienced (10.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 34.2yrs | US$3.78m | 6.4% $ 120.5m | |
| President & Director | 25.3yrs | US$1.27m | 0.029% $ 550.4k | |
| Founder and Chairman of Scientific Advisory Board | no data | US$138.40k | no data | |
| Independent Director | 23.6yrs | US$259.00k | 0.016% $ 307.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 17.9yrs | US$254.50k | 0.27% $ 5.0m | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 3.9yrs | US$235.50k | 0.0063% $ 118.6k |
23.6yrs
Average Tenure
70yo
Average Age
Experienced Board: LMAT's board of directors are seasoned and experienced ( 23.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 03:25 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LeMaitre Vascular, Inc. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Petusky | Barrington Research Associates, Inc. |
| Jan Wald | Benchmark Company |
| Raymond Myers | Benchmark Company |